Engages in research, development, manufacturing and marketing of biopharmaceutical products 3SBio, Inc. engages in the provision of biopharmaceutical business. It develops, research, manufactures and market biopharmaceutical products which are used in the field of medicine particularly in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. The company was founded by Jing Lou and Dan Lou in 1993 and is headquartered in Shenyang, China.
Shareholders 3SBio Inc (1530 - Stock Exchange of Hong Kong)
Name Shares % CITIC Private Equity Funds Management Co., Ltd. 712,258,360
28.3% Jing Lou, MD, PhD 659,367,030
26.2% Bo Tai 115,549,920
4.59% Bin Huang 33,919,350
1.35% Dong Mei Su, PhD 26,403,630
1.05% HSBC Global Asset Management (Hong Kong) Ltd. 14,285,500
0.57% Columbia Management Investment Advisers LLC 4,482,000
0.18% Threadneedle Asset Management Ltd. 2,439,705
0.097% Newton Investment Management Ltd. 403,000
0.016% Deutsche Asset Management (UK) Ltd. 305,500
3SBio Inc. (ADR) : Connections
Excel Partner Holdings Ltd.
Taizhou Huan Sheng Investment Management Co., Ltd.
Shenzhen Baishitong Technology Development Co., Ltd.
Shanghai Aoxi Technology Information Consulting Co., Ltd.
Guangdong Sciprogen Bio-Pharmaceutical Technology Co., Ltd.
Ample Harvest Investments Ltd.
Liaoning Sunshine Bio-Pharmaceutical Co. Ltd.
Zhejiang Sunshine Pharmaceutical Co., Ltd.
Mudanjiang Youbo Pharmaceutical Co., Ltd.
Shenzhen Sciprogen Bio-Pharmaceutical Co., Ltd.
Ontario Institute for Cancer Research
Liaoning Sunshine Science & Technology Development Co. Ltd.
The Multiple Myeloma Research Foundation, Inc.
Hongkong Sansheng Medical Ltd.
Multiple Myeloma Research Consortium
Company contact information 3SBio, Inc. Shenyang Economy & Technology Dev No. 3 A1, Road 10 Shenyang, Liaoning 110027 Phone : +86.24.2581.1820 Fax : +86.24.2581.1821 Web : www.3sbio.com
© 2015 People , Fundamentals and Ownership